Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

17:54
10/09/16
10/09
17:54
10/09/16
17:54

Bristol-Myers reports data from CheckMate-057, CheckMate-017 trials

Bristol-Myers Squibb announced updated results from two pivotal Phase 3 studies, CheckMate -057 and CheckMate -017, which showed more than one-third of previously treated metastatic non-small cell lung cancer patients in both trials experienced ongoing responses with Opdivo, compared to no ongoing responses in the docetaxel arm. The median duration of response with Opdivo versus docetaxel in CheckMate -057 was 17.2 months and 5.6 months, respectively, and in CheckMate -017 it was 25.2 months and 8.4 months, respectively. In CheckMate -057, patients with PD-L1 greater than or equal to 1% had a median DOR of 17.2 months and in patients with PD-L1 less than 1%, it was 18.3 months. In both studies, durability of response was observed in both PD-L1 expressors and non-expressors, and in CheckMate -057, one out of the four complete responses occurred in a patient with less than 1% PD-L1 expression. There were no new safety signals identified for Opdivo in the pooled safety analysis from both studies. No new treatment-related deaths occurred between one and two years' minimum follow-up despite the longer treatment exposure, and new events were observed in 11/418 patients with an additional one year of follow up. Patient-reported outcomes from CheckMate -057 were also presented. Findings show Opdivo provided better preservation of health status, health-related quality of life and symptom control versus docetaxel, as assessed by the EuroQoL-5 Dimensions, visual analog scale, and the Lung Cancer Symptom Score.

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

NCSM

NCS Multistage

10:16
04/28/17
04/28
10:16
04/28/17
10:16
Syndicate
NCS Multistage indicated to open at $18, IPO priced at $17 »

NCS Multistage (NCSM)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

$NYE

NYSE Market Internals

10:16
04/28/17
04/28
10:16
04/28/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

10:15
04/28/17
04/28
10:15
04/28/17
10:15
Syndicate
Breaking Syndicate news story on Cloudera »

Cloudera IPO indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

10:15
04/28/17
04/28
10:15
04/28/17
10:15
General news
FX Action: The dollar »

FX Action: The dollar was…

ANTM

Anthem

$177.90

-0.4 (-0.22%)

, CI

Cigna

$155.93

-0.28 (-0.18%)

10:13
04/28/17
04/28
10:13
04/28/17
10:13
Periodicals
Breaking Periodicals news story on Anthem, Cigna »

Appeals court upholds…

ANTM

Anthem

$177.90

-0.4 (-0.22%)

CI

Cigna

$155.93

-0.28 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

  • 18

    May

RDUS

Radius Health

$38.72

-0.5 (-1.27%)

10:12
04/28/17
04/28
10:12
04/28/17
10:12
Hot Stocks
FDA website shows approval of Radius Health's Tymlos »

Shares of Radius Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 02

    Jun

  • 30

    Jun

WDC

Western Digital

$85.71

1.1 (1.30%)

10:11
04/28/17
04/28
10:11
04/28/17
10:11
Recommendations
Western Digital analyst commentary  »

Western Digital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$10.50

0.14 (1.35%)

10:11
04/28/17
04/28
10:11
04/28/17
10:11
Options
Opening action in VIX August calls »

Opening action in VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

10:10
04/28/17
04/28
10:10
04/28/17
10:10
Syndicate
Breaking Syndicate news story on Cloudera »

Cloudera IPO indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

NVS

Novartis

$76.70

-0.36 (-0.47%)

10:10
04/28/17
04/28
10:10
04/28/17
10:10
Hot Stocks
FDA approves Novartis' combination treatment for AML »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 05

    May

  • 07

    May

  • 06

    Jun

  • 26

    Jun

SWKS

Skyworks

$104.20

1.23 (1.19%)

, SSNLF

Samsung

10:09
04/28/17
04/28
10:09
04/28/17
10:09
Recommendations
Skyworks, Samsung analyst commentary  »

Skyworks price target…

SWKS

Skyworks

$104.20

1.23 (1.19%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 30

    May

RDUS

Radius Health

$38.72

-0.5 (-1.27%)

10:07
04/28/17
04/28
10:07
04/28/17
10:07
Hot Stocks
Radius Health jumps after FDA posts approval of Tymlos 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 02

    Jun

  • 30

    Jun

ORLY

O'Reilly Automotive

$257.19

-7.88 (-2.97%)

10:02
04/28/17
04/28
10:02
04/28/17
10:02
Recommendations
O'Reilly Automotive analyst commentary  »

O'Reilly Automotive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

MHK

Mohawk

$229.91

-8.97 (-3.76%)

10:01
04/28/17
04/28
10:01
04/28/17
10:01
Technical Analysis
Mohawk testing uptrend support line following earnings »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

10:01
04/28/17
04/28
10:01
04/28/17
10:01
General news
Consumer Sentiment Index data reported »

April Consumer Sentiment…

CL

Colgate-Palmolive

$72.10

-1.2 (-1.64%)

10:01
04/28/17
04/28
10:01
04/28/17
10:01
Options
Call buyer in Colgate as shares fall on earnings »

Call buyer in Colgate as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

EEX

Emerald Expositions Events

10:00
04/28/17
04/28
10:00
04/28/17
10:00
Syndicate
Breaking Syndicate news story on Emerald Expositions Events »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

IVC

Invacare

$14.85

1.6 (12.08%)

09:59
04/28/17
04/28
09:59
04/28/17
09:59
Upgrade
Invacare rating change  »

Invacare upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 18

    May

CVNA

Carvana

09:58
04/28/17
04/28
09:58
04/28/17
09:58
Syndicate
Breaking Syndicate news story on Carvana »

Carvana opens at $13.50,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

EFX

Equifax

$134.84

-1.35 (-0.99%)

09:56
04/28/17
04/28
09:56
04/28/17
09:56
Downgrade
Equifax rating change  »

Equifax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 04

    May

EEX

Emerald Expositions Events

09:55
04/28/17
04/28
09:55
04/28/17
09:55
Syndicate
Breaking Syndicate news story on Emerald Expositions Events »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

09:55
04/28/17
04/28
09:55
04/28/17
09:55
General news
U.S. Chicago PMI increased 0.6 points to 58.3 in April »

U.S. Chicago PMI…

CSGP

CoStar Group

$236.71

17.35 (7.91%)

09:53
04/28/17
04/28
09:53
04/28/17
09:53
Recommendations
CoStar Group analyst commentary  »

CoStar Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

BOKF

BOK Financial

$85.04

-0.42 (-0.49%)

09:51
04/28/17
04/28
09:51
04/28/17
09:51
Upgrade
BOK Financial rating change  »

BOK Financial upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

OCLR

Oclaro

$7.93

0.01 (0.13%)

09:51
04/28/17
04/28
09:51
04/28/17
09:51
Recommendations
Oclaro analyst commentary  »

Oclaro estimates lowered …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.